The performance of companies tied to Sildenafil's history presents a challenging investment scenario . While the initial surge generated substantial returns , generic alternatives have significantly diminished revenue. Investing in associated pharmaceutical businesses now requires a discerning assessment of patent rights , evolving medical shifts ,